妊娠中の女性における因子Vライデン変異のスクリーニングの費用対効果

Peter Clark1, Sara Twaddle, Isobel D Walker

  • 1Department of Transfusion Medicine, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. peter.clark@snbts.csa.scot.nhs.uk

PubMed
まとめ

妊娠中の女性に対して,ファクターV・ライデン (FVL) 変異のスクリーニングを行うことは,費用対効果が高くありません. 普遍的または選択的スクリーニング戦略は,追加の管理コストを正当化するために十分な血管イベントを防ぐことができません.

関連する概念動画

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...